BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 330 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,690,000 | -22.4% | 97,175 | -25.2% | 0.08% | -19.4% |
| Q2 2022 | $18,930,000 | +98.2% | 129,919 | +61.3% | 0.10% | +81.5% |
| Q1 2022 | $9,551,000 | -43.2% | 80,552 | -33.9% | 0.05% | -41.3% |
| Q4 2021 | $16,805,000 | -33.5% | 121,946 | -33.0% | 0.09% | -43.6% |
| Q3 2021 | $25,268,000 | +2120.4% | 181,904 | +1451.2% | 0.16% | +1937.5% |
| Q2 2021 | $1,138,000 | -33.2% | 11,727 | -53.0% | 0.01% | -33.3% |
| Q1 2021 | $1,704,000 | -22.8% | 24,930 | -3.1% | 0.01% | -36.8% |
| Q4 2020 | $2,206,000 | -49.3% | 25,735 | -61.6% | 0.02% | -47.2% |
| Q3 2020 | $4,355,000 | -31.9% | 66,996 | -23.4% | 0.04% | -50.7% |
| Q2 2020 | $6,394,000 | +2135.7% | 87,453 | +941.1% | 0.07% | +812.5% |
| Q1 2020 | $286,000 | -57.1% | 8,400 | -35.2% | 0.01% | -60.0% |
| Q1 2019 | $667,000 | – | 12,964 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |